Table 3 Dose schedules and dose-limiting toxicities of MK-2206 in combination therapy
Treatment arm | MK-2206 dosing schedule | Evaluable patients | Dose-limiting toxicities | |
|---|---|---|---|---|
1 | Carboplatin AUC 6 | 45 mg QODb | 5 | 1; rash |
60 mg QODb | 4 | 3a; rash, febrile neutropenia (2) | ||
90 mg Q3W | 5 | 1; rash | ||
Paclitaxel 200 mg/m2 | ||||
135 mg Q3W | 5 | 1; TCP | ||
200 mg Q3W | 5 | 2; rash | ||
2 | Docetaxel 75 mg/m2 | 45 mg QODb | 5 | 3; febrile neutropenia |
Docetaxel 60 mg/m2 | 90 mg Q3W | 3 | 0 | |
135 mg Q3W | 3 | 0 | ||
200 mg Q3W | 4 | 1; tinnitus | ||
3 | Erlotinib 100 mg | 45 mg QODc | 8 | 2; rash, stomatitis |
135 mg QW | 4 | 0 | ||
Erlotinib 150 mg | 45 mg QODc | 3 | 1; rash | |
135 mg QW | 5 | 1; rash | ||